

Minutes of Pre-bid Meeting
For Procurement of FIRST LINE ANTI TB DRUGS
FOR NTEP FOR THE YEAR 2022-23
Tender Reference No: CMSS/PROC/2022-23/NTEP/014, dated 21.09.2022
Pre-bid Meeting held on 28.09.2022 at 11:00 AM

1. Following officials were present during the Pre-bid meeting:-

- (i) Ms. Anjana, GM (Procurement), CMSS
- (ii) Mr. D. Mohapatra, GM (Finance), CMSS
- (iii) Dr. R P Joshi, DDG, NTEP
- (iv) Ms. Kavita, Consultant, NTEP
- (v) Ms. Akanksha Jain, AGM (QA), CMSS
- (vi) Mr. Lava Mishra, AGM (Proc), CMSS

2. Following representative from prospective bidder was present during the Pre-bid meeting:-

Sr. No.	Name of Representative	Name of firm
1	Mr. Ajay Agarwal, Mr. Saniket & Mr. Amit Krishna	M/s Macleods Pharmaceuticals Ltd.
2	Mr. Arun	M/s Unicure India

3. Queries from following prospective firm was received via email: -

Sr. No.	Name of the bidders
1	M/s Centurion Laboratories Pvt Ltd.
2	M/s Macleods Pharmaceuticals Ltd.
3	M/s Oxalis Labs
4	M/s Garia Medical Agency

4. Points raised by representative of prospective bidder were discussed. After due consideration of the queries, the Clarification/Amendments are follows: -

ANNEXURE-1

Sr. No.	As per tender	Tender clause no. &Pg no.	Bidder's Query	Bidder's Name	Clarification/Amendments
1	The details of the annual required quantity of items are shown in Annexure-I (i) Central Medical Services Society (CMSS) will have the right to increase or decrease up to 25% of the quantity of goods and/or services specified in the schedule of requirements without any change in the unit price or other terms and conditions at the time of award of contract.	10.1 (i) &Pg no. 25	This clause may please be amended and condition of decrease of quantities should be removed as we need to book raw material against payment of advances because of high fluctuations in raw material market and decrease of quantities affects our costing.	M/s Macleods Pharmaceuticals Ltd. M/s Oxalis Labs	No changes.

2	In exceptional situation where the requirement is of an emergent nature and/ or it is necessary to ensure continued supplies from the existing vendors, the purchaser reserves the right to place repeat order up to 50% of the quantity of the goods and/or services contained in the running tender/contract up to a period of twelve months from the earliest date of Long Term agreement (LTA) at the same rate or a rate negotiated (downwardly) with the existing vendors considering the reasonability of rates based on prevailing market conditions and the impact of reduction in duties and taxes etc.	10.1 (ii) &Pg no. 25	This clause may please be amended and condition of placing of 50% additional quantities may please be removed because our costing is based on the indicative quantities in the tender to be kept effective till the validity of the bid.	M/s Macleods Pharmaceuticals Ltd. M/s Oxalis Labs	No changes.
3	17.5 Lot/Tranche/PO wise Part payments for supply will be considered only after completion of supply of at least 50% quantity ordered in the individual Purchase Order/Lot/Tranche PROVIDED original consignee receipts (or on GeM by consignee for the receipt, with original CRC to be submitted before next payment is released) are produced and the quality pass reports of Standard Quality on samples testing are received from approved laboratories of CMSS.	17.5 &Pg no. 35	Please consider part payment after supply of 10% of item order in the individual tranche/lot in the purchase order provided report of standard quality of samples testing are received from approval laboratories of CMSS as the quantities to be supplied under schedule 1 are very large and release of payment on completion of 50% of the supplies in the individual tranches/lot largely affect our working capital requirements, hence would request you to consider release of payment on completion of 10% supplies (of standard quality) in the individual tranches/lot as being done in the case of large quantities for DSTB-CP/IP.	M/s Macleods Pharmaceuticals Ltd. M/s Oxalis Labs	No changes.
4	18.2 If the supply reaches the designated consignee places or CMSS Warehouse after scheduled delivery date mentioned in LOA/P.O, liquidated damages will be levied @ 2.5% per week to be applied proportionately on per day basis up to a maximum of 10% of P.O. Cost, irrespective of the fact that whether the CMSS has suffered any damage/ loss or not, on account of delay in effecting supply. If the last scheduled delivery day happens to be a holiday the supply will be accepted on the next working day without any penalty.	18.2 &Pg no. 37	Liquidated damages 2.5% per week is very high. Please consider 0.25% per week to maximum 10%. 2.5% per week penalty is too much high. Kindly decrease percentage of penalty per week.	M/s Macleods Pharmaceuticals Ltd. M/s Oxalis Labs M/s Centurion Laboratories Pvt Ltd.	No changes.

5	Blister Strips should have perforations and spacing between tablets enough to allow removal by patients with finger deformities and easier separation of individual tablets from the strips.	Annexure 1A- Technical Specification &Pg no. 84	We have supplied without perforations of individual tablets earlier. Therefore request you to remove the said conditions.	M/s Macleods Pharmaceutica ls Ltd. M/s Oxalis Labs	Agreed.
6	<p>Storage and Shelf-life:</p> <p>At least 5/6th of the total stipulated shelf life must remain at the time of arrival at the consignee's warehouse. The supplier will provide manufacturer's test data substantiating the claimed shelf life in the proposed package (blister pack). Not only the pharmaceuticals, but also the packaging components should also conform to specifications suitable for use in acclimate prevailing in India. The product supplied should have been subjected to long term stability conditions as per below requirements: Study Storage condition. Long Term Stability 25 °C ± 2 °C/60% RH ± 5% RH Or 30 °C ± 2 °C/65% RH ± 5% RH</p>		We have long term stability data as per USP. We would like to bring to your kind attention that the quality and performance parameters in IP/BP/USP are all same and the specifications available in the stability data assigned by Macleods pharmaceuticals Ltd. are all well covered and very well in limit also. Hence request you to please consider.	M/s Macleods Pharmaceutica ls Ltd. M/s Oxalis Labs	Please refer ANNEXURE-2.
7	<p>Schedule of Requirement</p> <p>LOT 1: 25% quantity to be delivered within 60 days from issue of LOA LOT 2: 25% quantity to be delivered within 160-180 days from issue of LOA LOT 3: 25% quantity to be delivered within 270-300 days from issue of LOA LOT 4: 25% quantity to be delivered within 390-420 days from issue of LOA</p>	Annexure-I Delivery Schedule & Pg no. 43	<p>It would be better if 25% quantity are to be delivered within 120days from issue of LOA and rest of the quantities to be delivered within a gap of 60 days since the quantities are high. Request you to please consider the same.</p> <p>Delivery period should be increased up to 120 days as per past.</p>	M/s Macleods Pharmaceutica ls Ltd. M/s Oxalis Labs M/s Centurion Laboratories Pvt Ltd.	<p>LOT 1: 25% quantity to be delivered within 90 days from issue of LOA LOT 2: 25% quantity to be delivered within 150-180 days from issue of LOA LOT 3: 25% quantity to be delivered within 270-300 days from issue of LOA LOT 4: 25% quantity to be delivered within 390-420 days from issue of LOA</p>
8			Date of delivery should be considered from the date of PO & date of approval of artwork if submitted within 7 days of LOA, whichever is later and but not from the date of LOA as some time PO received after due date of first tranche mentioned in LOA.	M/s Centurion Laboratories Pvt Ltd.	No changes.
9			Accept payment documents with LR copy or docket number of courier because some time stamp is not visible on LR copy. You can verify this on your portal when stores	M/s Centurion Laboratories Pvt Ltd.	No changes.

			make entry on E-Aushadhi.		
10			As per new ICH guidelines, stability should be done on 30deg C \pm 2 deg C & 75% RH \pm 5%, kindly amend.	M/s Centurion Laboratories Pvt Ltd.	As per the specifications mentioned in the tender document.
11			Kindly consider our request and amend the shelf life.	M/s Centurion Laboratories Pvt Ltd.	As per the specifications mentioned in the tender document.
12			Allow non manufacturers (authorized dealers) to participate directly in the Tender.	M/s Garia Medical Agency	No changes.
13			Allow manufacturers to participate directly and appoint authorized dealers on their behalf to supply (in this case the orders are to be issued in the name of authorized dealer and dealer will raise the invoices)	M/s Garia Medical Agency	No changes.

Note: - Above changes will be part of the tender document.

GM (Procurement)

ANNEXURE-2

In addition to above, following changes are made in the published tender document: -

Sr. No.	Tender clause no. & Pg no.	Item Name	As per Tender	After amendment
1.	Annexure -1A & Pg No. 45	DSTB IP (Adult)-4FDC & DSTB CP (Pediatrics)-2FDC		Additional clause of the technical specification DSTB IP & CP – (Adult & Paediatrics respectively i.e. 4FDC & 3FDC (Adult and 3FDC and 2FDC Paediatric): - <i>“If the tendered drug is in Indian Pharmacopoeia (IP), then the manufacturing license has to be submitted in IP only. For drugs which are not available in IP, other official Pharmacopoeia (s) are applicable. If a drug is not available in any of the official pharmacopoeia, ‘In House’ standards are applicable as per Drugs and Cosmetics Act 1940 and Rules there under”</i>
2.	6.1 (m) & Pg No. 18	DSTB IP (Adult)-4FDC	Long Term (Real Time) Stability Data of the quoted product in specified packing for at least for 3 batches, to support shelf life.	Amended as: - Long Term (Real Time) Stability Data of the quoted product in IP [or BP/USP/ Other International pharmacopoeia (as FDC)] in specified packing for at least for 3 batches, to support shelf life is to be submitted.
3.	6.1 (m) & Pg No. 18	DSTB CP (Pediatrics)-2FDC	Long Term (Real Time) Stability Data of the quoted product in specified packing for at least for 3 batches, to support shelf life.	Amended as: - Long Term (Real Time) Stability Data in any pharmacopoeia [if quoted drug (as FDC) is not available in IP] in specified packing for at least for 3 batches, to support shelf life. If quoted drug is not available in any pharmacopoeia, in-house Long Term (Real Time) Stability Data (as FDC with component as per technical specification i.e. IP/BP/USP/ Other International pharmacopoeia) in specified packing for at least for 3 batches, to support shelf life is to be submitted.

Note: - Apart from above, all other terms & conditions of tender document will remain unchanged.

GM (Procurement)